Bollet A J
Semin Arthritis Rheum. 1985 Feb;14(3 Suppl 1):25-8. doi: 10.1016/0049-0172(85)90057-5.
Serum levels of piroxicam were observed for periods of one to 15 months in patients who had a variety of rheumatic diseases. At a dose of 20 mg per day, patients' serum levels ranged from undetectable (less than 0.5) to 24.8 micrograms/mL. Mean serum levels did not vary with age or body weight and remained relatively constant in individual subjects during the period of follow-up. Thus, there is no justification for altering the recommended dose of 20 mg based solely on patient age or weight. Concomitant administration of salicylate or acetaminophen was associated with decreased serum levels of piroxicam, but other drugs, such as diuretics, prednisone, and cimetidine, had no discernible effect on piroxicam levels. Gastrointestinal toxicity, requiring discontinuance of piroxicam therapy, occurred in only four patients, and there was no association between serum levels of piroxicam and gastrointestinal toxicity.
在患有各种风湿性疾病的患者中，观察了吡罗昔康的血清水平，观察期为1至15个月。在每天20毫克的剂量下，患者的血清水平范围从检测不到（低于0.5）到24.8微克/毫升。平均血清水平不随年龄或体重变化，并且在随访期间个体受试者中保持相对恒定。因此，没有理由仅根据患者年龄或体重改变推荐剂量20毫克。同时服用水杨酸盐或对乙酰氨基酚与吡罗昔康血清水平降低有关，但其他药物，如利尿剂、泼尼松和西咪替丁，对吡罗昔康水平没有明显影响。仅4名患者出现需要停用吡罗昔康治疗的胃肠道毒性，且吡罗昔康血清水平与胃肠道毒性之间没有关联。
